Indiana University School of Medicine scientists have developed a new method that shifts the behavior of immunosuppressive cells in tumors, turning them from cancer protectors into tumor fighters.
Suicide is a leading cause of death in postpartum women—and it is a preventable one. It is estimated that nearly half of mothers experiencing perinatal depression are undiagnosed and are not receiving treatment. But when women are given vital mental health tools in an accessible manner, their deaths can be prevented.
Researchers have harnessed the power of artificial intelligence to tackle one of the most complex challenges in immunology: predicting how T cells recognize and respond to specific peptide antigens.
In a landmark study of Hispanic and Latino adults, researchers at University of California San Diego School of Medicine have identified a link between self-reported cognitive decline and blood-based biomarkers, which could pave the way for a simple blood test to help diagnose Alzheimer’s disease and related dementias.
A research team has developed an implantable wireless neural interface capable of delivering drugs precisely to deep regions of the brain.
Post-traumatic stress disorder (PTSD) is a mental health disorder triggered by traumatic experiences such as accidents, disasters, or violence. Exposure therapy, a scientifically validated treatment for PTSD, involves the gradual re-exposure of patients to trauma-related cues to reduce anxiety and avoidance behaviors.
Researchers at University of Tsukuba have demonstrated for the first time that brain regions responsible for high-level motor planning and preparation, such as the premotor cortex, are activated when a cyborg-type robot is volitionally controlled.
The NHS announced a first-of-its-kind initiative in England, offering automated insulin delivery systems for pregnant women with diabetes.
Pulse Biosciences (Nasdaq:PLSE) announced today that the FDA granted investigational device exemption (IDE) for its nanosecond pulsed field ablation (nsPFA) system.
Lifeward (Nasdaq:LFWD) announced today that it received CE mark approval for its ReWalk 7 personal exoskeleton.